# Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma

> **NCT04239170** · PHASE2 · UNKNOWN · sponsor: **Peking University** · enrollment: 84 (estimated)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** Camrelizumab(SHR-1210)

## Key facts

- **NCT ID:** NCT04239170
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2020-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04239170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04239170, "Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04239170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*